Express delivery of more than half of the symptoms of vitiligo patients improved by 50%, and topical JAK inhibitors announced the complete phase 3 clinical results

▎The content team editor of WuXi AppTec recently, Incyte announced the complete results of a pivotal Phase 3 clinical trial of its topical JAK inhibitor ruxolitinib cream (ruxolitinib, English trade name Opzelura) in the treatment of patients with vitiligo over 12 years old
.

The results of the test showed that Rucotinib cream significantly improved the recovery of facial pigmentation of patients at 24 weeks, with more patients achieving at least 75% improvement in symptoms
.

The press release pointed out that it may become the first treatment to help patients with vitiligo restore skin pigment
.

Vitiligo is a chronic autoimmune disease.
Because of the loss of melanocytes in the epidermis, melanin cannot be produced, and white spots appear on the skin
.

Vitiligo affects approximately 0.
5% to 2.
0% of the world's population, there is no effective cure, the existing treatments are mainly used to improve the color, such as immunosuppressive therapy, ultraviolet A (UVA) irradiation using sunscreens or other covering
.

Rucotinib cream is a JAK1/JAK2 preparation for external use.
It has recently been approved by the US FDA for the treatment of mild to moderate atopic dermatitis, becoming the first JAK inhibitor for external use approved by the FDA
.

Excessive activation of JAK signaling pathway has been shown to drive inflammation and participate in the pathogenesis and progression of vitiligo
.

▲The molecular structure of Rucotinib (picture source: Jü, Public domain, via Wikimedia Commons) Rucotinib cream reached the primary and all key secondary endpoints in two phase 3 clinical trials.
Specifically: At week 24, 29.
9% of patients treated with Rucotinib cream reached the standard of at least 75% improvement in facial vitiligo symptoms
.

More than 51% of patients in the Rucotinib group improved their facial vitiligo symptoms by at least 50%, and more than 15% of patients improved their facial symptoms by more than 90%
.

Compared with placebo, more patients in the Lucitinib group achieved an improvement in the systemic vitiligo area score by more than 50%
.

"We are very pleased to share the complete 24 weeks results of this Phase 3 clinical development project for the first time.
It shows that Rucotinib cream significantly improves facial and systemic pigment recovery
.

" said Dr.
Jim Lee, Vice President of Incyte's Inflammation and Autoimmunity Department.
We look forward to working with regulatory agencies to bring the first approved treatment directly to the problem of pigment restoration to patients
.

"Reference: [1] Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo.
Retrieved October 2, 2021, from https:// Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.

This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.

This article is not a treatment recommendation either
.

If you need guidance on the treatment plan, please go to a regular hospital for treatment
.